Pragmatic clinical trials to optimise treatments for patients with refractory cancers
This program, "Pragmatic clinical trials to optimise treatments for patients with refractory cancers" (HORIZON-MISS-2022-CANCER-01-03), is part of the Horizon Europe Mission on Cancer. It focuses on funding pragmatic clinical trials to develop and implement more effective, patient-centred, and affordable treatment interventions for refractory cancers across EU Member States and Associated Countries. The primary goal is to improve outcomes and quality of life for cancer patients in real-world clinical practice.
Who is Funded
This funding program targets a broad range of entities and individuals dedicated to advancing cancer treatment through pragmatic clinical trials. The primary beneficiaries are cancer patients, particularly those with refractory cancers, and their caregivers, with a strong emphasis on improving their quality of life. The program is open to applicants from EU Member States and Associated Countries, aiming to foster collaborative research and facilitate the implementation of effective treatment strategies across diverse healthcare systems.
What is Funded
This program supports research and innovation actions focused on pragmatic clinical trials for refractory cancers, aiming to optimize treatments and improve patient quality of life. Projects should evaluate effective and affordable interventions suitable for real-world clinical practice, with a focus on patient-centered outcomes.
Type and Scope of Funding
This program offers grant funding, with a substantial budget allocation to support pragmatic clinical trials. Individual projects can receive significant contributions, and successful trials are expected to be completed within five years.
Conditions and Requirements
Applicants must adhere to specific conditions regarding proposal admissibility, eligibility, financial capacity, and ethical considerations. The program encourages collaborative consortia and emphasizes the integration of social sciences and humanities, as well as considering sex- and gender-related issues.
Application Procedure
The application process follows a single-stage submission and evaluation, with specific award criteria that prioritize not only ranking but also strategic objectives, such as addressing cancer in children, adolescents, and young adults.
Legal Basis
The program operates under the comprehensive legal framework of Horizon Europe, established by specific EU regulations and decisions, ensuring a robust and transparent governance structure for its research and innovation activities.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
6,000,000 €
Allocated Budget:
60,000,000 €
Deadline:
07.09.2022
Award Channel:
Framework Programme Call
Region:
EU regions, Member States, and Associated Countries
Sectors:
Healthcare, Medical Technology, Research and Development, Social Enterprises
Beneficiaries:
Cancer patients, caregivers, healthcare professionals, academia, national healthcare providers, policymakers, authorities
Application Type:
Consortium Required
Funding Stages:
Experimental Development, Implementation, Service Delivery
Funding Provider
Program Level:
European Union
Funding Body:
European Commission
Managed By:
Unknown
Additional Partners:
The provided data lists several organizations offering expertise for collaboration, including: UNIVERSIDAD DE JAEN, NanoSciTec GmbH, INTERSPREAD GMBH, LIFE SCIENCE NETWORK GGMBH, UNIVERSIDAD CARLOS III DE MADRID, CONSULTECH TECHNOLOGIEBERATUNG GMBH, TECH2MARKET SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA, NUROMEDIA GMBH, SYNLAB International GmbH, Biome Diagnostics GmbH, SYNYO GmbH, Evidence Synthesis Group, INITIO CELL BIYOTEKNOLOJI ANONIM SIRKETI, ISTANBUL TEKNIK UNIVERSITESI, SOLUTOPUS - RECURSOS E DESENVOLVIMENTO LDA, REPADO LOGISMIKOTECHNIKI-IPIRESIESEREYNAS KAI ANAPTIXIS EPE, TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH, ASOCIATIA DE STANDARDIZARE DIN ROMANIA, BEIA CONSULT INTERNATIONAL SRL, Innoplexus, Green NanoTech, Academia La Hoz - Carlos Lorenzo de la Hoz, Red Hospitalaria Recoletas, MAUDE STUDIO, SL, CONCEPTTO DESARROLLO ESTRATÉGICO, SL, NATIONAL CANCER INSTITUTE, Fundación Fernando Núñez, ONCOMPASS MEDICINE HUNGARY KORLATOLT FELELOSSEGU TARSASAG, UNIVERSIDAD DE CADIZ, ARTIFICIAL INTELLIGENCE EXPERT SRL, Papanikolaou Hospital, Kelvin Health Inc., Medical Physics Unit - Second department of Radiology MEDICAL SCHOOL - ATHENS UNIVERSITY, OPENCOM I.S.S.C., FUNDACION PRIVADA HOSPITAL ASIL DEGRANOLLERS, Flow Analysis and Simulation Team, EXO LAB ITALIA S.R.L., BCN HEALTH ECONOMICS & OUTCOMES RESEARCH S.L., MOSAIQUES DIAGNOSTICS GMBH, OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG, Dávid SZTAHÓ, SHINE 2EUROPE LDA, LifestylediagnostiX, C4G - CONSULTING AND TRAINING NETWORK, LDA, C.I.P. CITIZENS IN POWER, SentiGeek P.C., ORGANIZACION DE PROFESIONALES, AUTÓNOMOS Y EMPRENDEDORES DE EXTREMADURA, GC GENOMICS GMBH, GC GENOMICS ESPAÑA, SL, Grupo Colabora Formación y Proyectos, SL, VISILAB, INSTITOUTO ANAPTIXIS EPICHEIRIMATIKOTITAS ASTIKI ETAIREIA, Keralty, SPITALUL CLINIC JUDETEAN DE URGENTA PIUS BRINZEU TIMISOARA, Salumentis OG, ELVESYS, Metabio IKE, Rhino Health Ltd
Website: